| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Crescent Biopharma (NASDAQ:CBIO) reported quarterly losses of $(1.27) per share which beat the analyst consensus estimate of $(...
Crescent Biopharma, Inc. ("Crescent" or the "Company") (Nasdaq: CBIO), a biotechnology company dedicated to rap...
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Crescent Biopharma (NASDAQ:CBIO) with a Buy and maintains $25 ...
Jefferies analyst Akash Tewari initiates coverage on Crescent Biopharma (NASDAQ:CBIO) with a Buy rating and announces Price ...
HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Crescent Biopharma (NASDAQ:CBIO) with a Buy rating ...